ALK and non-small cell lung carcinoma: To investigate whether longitudinal monitoring of cfDNA‐NGS could predict the response and resistance of TKI therapy in ALK+ NSCLC, we recruited prospectively 92 patients with ALK+ advanced NSCLC determined by standard tissue testing and planned for TKI therapy.